While the stereotype of the "heroin junkie" has shaped the imagery of opioid addiction in North America for almost a century (3, 4) , the review by Fischer and others (5) instructs us that the contemporary phenomenon of illicit opioid use in Canada is actually much more diverse. As shown by data from the multisite OPICAN cohort, heroin is just one of a wide spectrum of opioid and nonopioid drugs consumed by today's illicit opioid users in cities across Canada. In fact, most opioids reported for illicit use are prescription opioids and thus originate directly or indirectly from the medical system.
Given this reality, we need to reevaluate prevention and control strategies. A key aspect of the wider morbidity profile of illicit opioid use is that the associated morbidity exceeds by far the problem of drug dependence. Both infectious disease-primarily hepatitis C (HCV) and HIV-and psychiatric comorbidity (predominantly in the form of depression and personality disorders) are highly prevalent among illicit opioid users, underlining the need for multimorbidity interventions (6, 7) , a challenge that is rarely adedquately met, at best. Fischer and colleagues also illustrate the dynamics of social variables in influencing harms related to illicit opioid use, namely, that key social determinants such as housing status often critically shape the degree of harm outcomes (for example, overdose risks) in the target population (8) . All told, illicit opioid use in the current context imposes a great deal of social harm on Canadian society (for example, in the form of social costs), and both health harms and health costs have markedly increased over the past decade (9) . Importantly, the level of harms and costs related to illicit opioid use is determined extrinsically by the laws and social policies governing this phenomenon, which makes the issue a matter of social choice. This can be observed in Canadian society, where illicit drug dependence is approached primarily as an enforcement rather than a health matter, in that a street-opioid addict is defined as a criminal and is as likely to encounter interventions imposed by the criminal justice system as interventions from the treatment system. Therefore, reducing the societal causes and harms associated with illicit opioid use in Canada will eventually require changes to repressive Canadian drug-control legislation that will render illicit drug dependence first and foremost a public health issue (10, 11) .
One further important point made in the Fischer and others paper (5) is that trying to gauge the real extent of the opioid abuse problem by looking at the more visible street-drug users may only reveal a small proportion of the affected population. Anecdotal evidence from Canada and recent epidemiologic data from the United States have suggested that the abuse or misuse of prescription opioids in the general North American population likely far exceeds the size of street opioid-user populations (currently estimated at < 0.5% of the general population) (12) . Even less empirical knowledge exists about the harmful consequences of the opioid abuse phenomenon in the general population. These observations underline the urgent need to meaningfully reframe the scope and definition of the opioid abuse problem in Canada and to gather and monitor the necessary empirical data on prevalence and harmful consequences to allow for evidence-based prevention, treatment, and policy development.
Also in this issue, van den Brink and Haasen (13) provide a comprehensive summary of the current treatment options for opioid dependence, based on data from scientific research conducted around the world. Evidently, the landscape of available treatments has become large and diverse. Even within the primary field of opioid maintenance therapy, which has emerged as the first-line response generating most favourable long-term treatment outcomes for the target populations under study, the diversity of interventions has grown considerably in recent years, with agents like buprenorphine, morphine, or diamorphine now enriching a field that was for several decades the sole territory of methadone maintenance therapy (MMT) in most jurisdictions (14) (15) (16) . It is little known but worth mentioning in this context that, although methadone treatment for opioid dependence assumed its popular status through the widely published studies of Dole and Nyswander in the United States, it was first experimentally practised in the late 1950s by Dr Robert Halliday and his addiction-treatment team in Vancouver (17, 18) . Clearly, the primary challenge is now to make sense of the many treatment options available for illicit opioid dependence and to establish clear, evidence-based orientation guidelines for optimal patient treatment depending on the indications. Although some efforts have been made in this regard, much more is needed, and it will be an entirely separate challenge to then effectively disseminate these decision-making tools to the front-line practitioners increasingly involved in substance abuse treatment. The results of the Canadian heroinprescription North American Opiate Medication Initiative, expected for 2007, will show what role the controversial subject of medical heroin prescribing may play in this (19) . An entirely different challenge for therapeutic programming is the fact that most Canadian illicit opioid users are polydrug users involved in the intensive co-use of crack or cocaine (or both). Even though researchers have hunted for the "magic bullet" for many years (for example, in the form of contingency management) (20) , for most users, opioid maintenance treatment overall is not suited to therapeutically addressing crack or cocaine dependence. Rather, it reinforces it in many cases or leads to patients being penalized for co-use when in opioid treatment (for example, MMT) (4, 21) . In Canada, given the described epidemiologic reality of illicit opioid and other drug use, meaningful research and innovative intervention efforts are urgently needed in this regard.
An important supplementary point to van den Brink and
Haasen's review of opioid dependence treatment options is that they need to be effectively linked to interventions for the comorbidities that so prevalently accompany risky illicit opioid use. For example, illicit opioid use cooccurs with depressive symptoms or other psychiatric symptoms in every other case and often materializes as a form of unrecognized self-medication (22) . However, effective dual diagnosis and comorbidity treatment programs are the exception rather than the norm, underscoring the need for improvements in this area (23) . Another argument for urgently needed interdisciplinary integration of interventions comes from the field of infectious disease, specifically HCV. More than 3 in 4 new HCV transmissions in Canada occur among opioid and other drug injectors (24) . Pharmacotherapy for HCV has been shown to be feasible and effective for illicit drug users, but it requires tailored therapeutic approaches. Specifically, the high prevalence of depressive dispositions in HCV-infected drug-using patients requires the central involvement of mental health expertise in HCV-therapy delivery (25) . Further, studies have shown that embedding HCV therapy into MMT may facilitate good treatment adherence and outcomes for drug-using patients (26) . That only the smallest fraction of patients currently undergoing HCV treatment in Canada are former or current drug users emphasizes the urgency for progress in these fields.
In sum, illicit opioid dependence in Canada is a phenomenon that reaches far beyond addiction medicine or psychiatry yet requires the involvement and collaboration of these fields for effective delivery of preventive and therapeutic interventions to reduce individual and public health harms associated with this problem. We hope that the following review articles will help to educate this journal's distinguished readership about these issues and also to catalyze research, professional, and policy initiatives and progress toward tangible improvement in regard to the challenges raised.
